Evidence map›Paper›PMID 38634092›Full record

ArticleClinical case reports2024

Duodenal gastrointestinal stromal tumor presenting with life-threatening upper GI bleeding in a young patient: A case report and literature review.

Samuel Addisu Abera, Amanuel Kassa Tadesse, Kirubel Addisu Abera, Kassa Berie Zegeye, Mohammed Alemu Ibrahim, Ashenafi Amsalu Feleke, Cheru Lilay Gebrehiwet, Segenet Bizuneh Mengistu, Hirut Tesfahun Alemu, Yohannis Derbew Molla

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Primary small bowel malignancies].Chirurgie (Heidelberg, Germany) · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Samuel Addisu AberaDepartment of Anatomic Pathology, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Amanuel Kassa TadesseDepartment of Anatomic Pathology, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Kirubel Addisu AberaDepartment of Anatomic Pathology, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Kassa Berie ZegeyeDepartment of Anatomic Pathology, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Mohammed Alemu IbrahimDepartment of Surgery, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Ashenafi Amsalu FelekeDepartment of Surgery, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Cheru Lilay GebrehiwetDepartment of Surgery, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Segenet Bizuneh MengistuDepartment of Internal medicine, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Hirut Tesfahun AlemuCollege of Medicine and Health Sciences University of Gondar Gondar Ethiopia.
Yohannis Derbew MollaDepartment of Surgery, College of Medicine and Health Sciences University of Gondar Gondar Ethiopia.ORCID https://orcid.org/0000-0001-7881-0538
University of Gondar · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key Clinical Message: Duodenal GISTs are rare and challenging tumors. Acute life-threatening upper GI bleeding is a possible presentation of duodenal GISTs. Surgery is the standard treatment for localized duodenal GISTs. Imatinib is an effective adjuvant therapy for duodenal GISTs. Abstract: GIST is the most common mesenchymal neoplasm of the gastrointestinal tract, accounting for 1%-2% of gastrointestinal tumors. They originate from the interstitial cells of Cajal and are rare in patients younger than 30 years. The stomach is the most common site, followed by the small intestine and colon. GISTs are caused by a gain-of-function mutation in the proto-oncogene receptor tyrosine kinase, with activating mutations in KIT being the most common. Most GISTs are asymptomatic. Even if gastrointestinal bleeding is the most common complication life-threatening hemorrhage is extremely uncommon. We present a case of a 31-year-old male patient presented with massive active hematemesis and melena with hemorrhagic shock. The patient presented with massive hematemesis and melena of 1 h duration. Endoscopy showed pulsating active bleeding from the third part of the duodenum which was difficult to manage via endoscopy. Histopathologic evaluation showed spindle cell type GIST. Intraoperatively, there was a nodular mass with active bleeding on the third part of the duodenum. Duodenectomy with end-to-end anastomosis was done. Discharged with no postoperative complication and was put on imatinib. There are considerable challenges that arise in the diagnosis and treatment of duodenal gastrointestinal stromal tumors (GISTs) when they present with life-threatening upper gastrointestinal hemorrhage. In order to achieve the best possible outcomes for patients, it is crucial to have a comprehensive understanding of the clinical presentation, diagnostic methods, and treatment approaches.

Indexed as

duodénumGISThematemesislife‐threateningshock

Identifiers

PMID38634092
PMCPMC11022307
OpenAlexW4394870057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.